Exchange: NASDAQ·Updated 07:51 PM EDT
News
all
press releases
KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook
KNSA lifted 2026 ARCALYST sales guidance as Q2 revenue surged, while advancing KPL-387 into Phase 3 to support its next growth driver.
Zacks
More News
MDGL Stock Down Despite Q2 Beat, MASH Drug Drives Top-Line Y/Y Growth
Madrigal beats Q2 estimates as Rezdiffra sales lift revenues 71% year over year, but shares fall as investors weigh slower commercial growth.
Zacks
Teva Q2 Earnings Lag Estimates, 2026 Revenue View Raised, Stock Rises
TEVA misses Q2 earnings estimates as Emalex acquisition costs weigh on profits, while innovative drugs drive a revenue beat and an increased 2026 sales outlook.
Zacks
Earnings Estimates Rising for Kiniksa Pharmaceuticals International, plc (KNSA): Will It Gain?
Kiniksa Pharmaceuticals International, plc (KNSA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Zacks
Alkermes Q2 Earnings Break Even, Revenues Beat Estimates, Stock Down
ALKS posts break-even Q2 earnings and tops revenue estimates as product sales surge, with Lumryz adding momentum. The company maintains its 2026 revenue view.
Zacks
Kiniksa Pharmaceuticals International, plc (KNSA) Q2 Earnings Match Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of 0.00% and +7.09%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
EU Clears AZN's Etcamah Combo for First-Line ER-Positive Breast Cancer
AstraZeneca secures EU approval for Etcamah in combination with a CDK4/6 inhibitor for first-line treatment of advanced ER-positive breast cancer patients.
Zacks
Zacks.com featured highlights include American Outdoor Brands, Cimpress, National Energy Services Reunited, CTO Realty Growth and Kiniksa Pharmaceuticals International
American Outdoor Brands, Cimpress, National Energy, CTO Realty and Kiniksa stand out for recent price strength backed by earnings growth and estimate revisions.
Zacks
PFE's Talzenna sNDA Gets FDA Priority Tag in Wider Prostate Cancer Use
Pfizer's Talzenna plus Xtandi combo wins FDA priority review for HRR gene-mutated metastatic castration-sensitive prostate cancer.
Zacks
Community Health Q2 Loss Wider Than Expected, 2026 View Lowered
CYH posts a wider-than-expected Q2 loss as revenues fall and the company cuts its 2026 revenue, EBITDA and earnings outlook.
Zacks

Advertisement|Remove ads.